R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: Results of a phase II Sarcoma Alliance for research through Collaboration study Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Bone Neoplasms
  • Receptor, IGF Type 1
  • Sarcoma, Ewing

abstract

  • R1507 was a well-tolerated agent that had meaningful and durable benefit in a subgroup of patients with ESFT. The identification of markers that are predictive of a benefit is necessary to fully capitalize on this approach.

publication date

  • December 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3236654

Digital Object Identifier (DOI)

  • 10.1200/JCO.2010.34.0000

PubMed ID

  • 22025149

Additional Document Info

start page

  • 4541

end page

  • 7

volume

  • 29

number

  • 34